Inhibition of the fibrinolytic and fibrinogenolytic activity of plasminogen activators in vitro by the antidotes ϵ-aminocaproic acid, tranexamic acid and aprotinin
- 1 April 1992
- journal article
- Published by Elsevier in Fibrinolysis
- Vol. 6 (2) , 79-86
- https://doi.org/10.1016/0268-9499(92)90064-o
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Aprotinin: An antidote for recombinant tissue-type plasminogen activator (rt-PA) active in vivoJournal of the American College of Cardiology, 1990
- Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS studyThe Lancet, 1990
- Intravenous bolus administration of recombinant tissue plasminogen activator to patients with acute myocardial infarctionCoronary Artery Disease, 1990
- Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarctionThe American Journal of Cardiology, 1989
- Binding of tissue-type plasminogen activator to lysine, lysine analogs, and fibrin fragmentsBiochemistry, 1989
- Thrombolytic Therapy: Current StatusNew England Journal of Medicine, 1988
- Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosisThe American Journal of Cardiology, 1986
- Clinical Application of Inhibitors of FibrinolysisDrugs, 1985
- Basis of antifibrinolytic therapyJournal of Clinical Pathology, 1980
- On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or α2-antiplasminThrombosis Research, 1979